Striverdi Respimat is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is protected by 25 US drug patents filed from 2014 to 2015. Out of these, 6 drug patents are active and 19 have expired. Striverdi Respimat's patents have been open to challenges since 31 July, 2018. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 16, 2030. Details of Striverdi Respimat's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7727984 | Medicaments for the treatment of chronic obstructive pulmonary disease |
Jan, 2027
(1 year, 8 months from now) | Active |
| US7220742 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(16 hours ago) |
Expired
|
| US7056916 | Medicaments for the treatment of chronic obstructive pulmonary disease |
Dec, 2023
(1 year, 5 months ago) |
Expired
|
| US7491719 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
Nov, 2023
(1 year, 6 months ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(5 years from now) | Active |
| US7837235 | Device for clamping a fluidic component |
Mar, 2028
(2 years from now) | Active |
| US9027967 | Device for clamping a fluidic component |
Mar, 2027
(1 year, 10 months from now) | Active |
| US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(1 year, 4 months from now) | Active |
| US7896264 | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(13 days from now) | Active |
| US8034809 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
May, 2025
(16 hours ago) |
Expired
|
| US7284474 | Piston-pumping system having o-ring seal properties |
Aug, 2024
(8 months ago) |
Expired
|
| US8044046 | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(1 year, 6 months ago) |
Expired
|
| US7786111 | Medicaments for the treatment of chronic obstructive pulmonary disease |
Nov, 2023
(1 year, 6 months ago) |
Expired
|
| US7988001 | Container provided with a pressure equalization opening |
Aug, 2021
(3 years ago) |
Expired
|
| US6988496 | Cartridge for a liquid |
Feb, 2020
(5 years ago) |
Expired
|
| US7802568 | Cartridge for a liquid |
Feb, 2019
(6 years ago) |
Expired
|
| US6977042 | Microstructured filter |
Aug, 2018
(6 years ago) |
Expired
|
| US6846413 | Microstructured filter |
Aug, 2018
(6 years ago) |
Expired
|
| US6149054 | Mechanical counter for a metering apparatus |
Dec, 2016
(8 years ago) |
Expired
|
| US6453795 | Locking mechanism for a spring-actuated device |
Dec, 2016
(8 years ago) |
Expired
|
| US6726124 | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) |
Expired
|
| US5964416 | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) |
Expired
|
| US7104470 | Device for producing high pressure in a fluid in miniature |
Oct, 2016
(8 years ago) |
Expired
|
| US6176442 | Device for mounting a component exposed to a pressurized fluid |
Oct, 2016
(8 years ago) |
Expired
|
| US7246615 | Atomising nozzle and filter and spray generating device |
May, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Striverdi Respimat's patents.
Latest Legal Activities on Striverdi Respimat's Patents
Given below is the list of recent legal activities going on the following patents of Striverdi Respimat.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Apr, 2023 | US8044046 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Apr, 2023 | US8034809 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Feb, 2022 | US7786111 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Nov, 2021 | US7727984 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Aug, 2020 | US7491719 |
| Patent Term Extension Certificate Critical | 16 Dec, 2019 | US7727984 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Apr, 2019 | US8044046 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Apr, 2019 | US8034809 |
| Notice of Final Determination -Eligible | 02 Apr, 2019 | US7727984 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Nov, 2018 | US7220742 |
FDA has granted several exclusivities to Striverdi Respimat. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Striverdi Respimat, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Striverdi Respimat.
Exclusivity Information
Striverdi Respimat holds 1 exclusivities. All of its exclusivities have expired in 2019. Details of Striverdi Respimat's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Several oppositions have been filed on Striverdi Respimat's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Striverdi Respimat's generic, the next section provides detailed information on ongoing and past EP oppositions related to Striverdi Respimat patents.
Striverdi Respimat's Oppositions Filed in EPO
Striverdi Respimat has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 12, 2012, by Knorr-Bremse Systeme Für Nutzfahrzeuge Gmbh. This opposition was filed on patent number EP2004006768W. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP05737938A | Apr, 2014 | Aechter, Bernd | Opposition rejected |
| EP2004006768W | Apr, 2012 | Knorr-Bremse Systeme für Nutzfahrzeuge GmbH | Revoked |
US patents provide insights into the exclusivity only within the United States, but Striverdi Respimat is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Striverdi Respimat's family patents as well as insights into ongoing legal events on those patents.
Striverdi Respimat's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Striverdi Respimat's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 16, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Striverdi Respimat Generics:
There are no approved generic versions for Striverdi Respimat as of now.
Alternative Brands for Striverdi Respimat
Striverdi Respimat which is used for managing symptoms of chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema., has several other brand drugs using the same active ingredient (Olodaterol Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Boehringer Ingelheim |
|
About Striverdi Respimat
Striverdi Respimat is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is used for managing symptoms of chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema. Striverdi Respimat uses Olodaterol Hydrochloride as an active ingredient. Striverdi Respimat was launched by Boehringer Ingelheim in 2014.
Approval Date:
Striverdi Respimat was approved by FDA for market use on 31 July, 2014.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Striverdi Respimat is 31 July, 2014, its NCE-1 date is estimated to be 31 July, 2018.
Active Ingredient:
Striverdi Respimat uses Olodaterol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Olodaterol Hydrochloride ingredient
Treatment:
Striverdi Respimat is used for managing symptoms of chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema.
Dosage:
Striverdi Respimat is available in spray, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.0025MG BASE/INH | SPRAY, METERED | Prescription | INHALATION |